Sign In
NVAX.US
id: 912

Novavax (NVAX) $47M Shareholder Settlement

It is still possible to file a late claim. The court will decide whether to accept late claims or not.
D. Maryland
Court
8:21-cv-02910
Case number
11 May 2021
Class period Start
19 Oct 2021
Class period End
18 May 2024
Claim deadline
Novavax (NVAX) agreed to settle $47M with investors to end claims over the vaccine approval issues.
Case Status
Accepting Late Claims
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
1.24
Filing date
12 November 2021
Lead Plaintiff Deadline
11 January 2022
Plaintiffs
Jeffrey A. Gabbert, Nuggehalli Balmukund Nandkumar, David Truong
Attorneys
Cohen Milstein Sellers & Toll PLLC (Washington, DC), Labaton Sucharow LLP (New York, NY), Pomerantz LLP (New York, NY), Portnoy Law Firm (Los Angeles, CA)
Defendants
Stanley C. Erck, Gregory F. Covino, John J. Trizzino, Gregory M. Glenn
Judge
Hon. Theodore D. Chuang
Administrator
Strategic Claims Services
Court hearing date
23 May 2024
Exclusion deadline
02 May 2024
Objection deadline
02 May 2024
Class wide damages
$2,351,400,000
Trades matching type
FIFO
+$47,000,000
Cash Settlement Amount

Frequently Asked Questions

Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine plat...

    Ticker
    NVAX.US
    ISIN
    US6700024010
    CIK
    1000694
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    700 Quince Orchard Road, Gaithersburg, MD, United States, 20878